BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21487323)

  • 1. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
    Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
    Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
    J Surg Res; 2003 Jul; 113(1):88-95. PubMed ID: 12943815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
    Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
    Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
    Ahn DW; Seo JK; Lee SH; Hwang JH; Lee JK; Ryu JK; Kim YT; Yoon YB
    Pancreas; 2012 Oct; 41(7):1048-57. PubMed ID: 22513291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    Tang ZY; Wu YL; Gao SL; Shen HW
    J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.